FR2889200B1 - Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique - Google Patents

Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique

Info

Publication number
FR2889200B1
FR2889200B1 FR0508029A FR0508029A FR2889200B1 FR 2889200 B1 FR2889200 B1 FR 2889200B1 FR 0508029 A FR0508029 A FR 0508029A FR 0508029 A FR0508029 A FR 0508029A FR 2889200 B1 FR2889200 B1 FR 2889200B1
Authority
FR
France
Prior art keywords
marker
cellular
proangiogenic
preparation
ligand
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
FR0508029A
Other languages
English (en)
French (fr)
Other versions
FR2889200A1 (fr
Inventor
Philippe Foubert
Jean Sebastien Silvestre
Ricousse Roussanne Sophie Le
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
INST VAISSEAUX ET DU SANG ASS
Universite Paris Diderot Paris 7
Original Assignee
INST VAISSEAUX ET DU SANG ASS
Universite Paris Diderot Paris 7
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to FR0508029A priority Critical patent/FR2889200B1/fr
Application filed by INST VAISSEAUX ET DU SANG ASS, Universite Paris Diderot Paris 7 filed Critical INST VAISSEAUX ET DU SANG ASS
Priority to ES06794234.2T priority patent/ES2565675T3/es
Priority to DK06794234.2T priority patent/DK1913130T3/en
Priority to EP06794234.2A priority patent/EP1913130B1/fr
Priority to PCT/FR2006/001837 priority patent/WO2007012764A2/fr
Priority to CA2616712A priority patent/CA2616712C/fr
Priority to AU2006273928A priority patent/AU2006273928B2/en
Priority to US11/996,862 priority patent/US8338169B2/en
Priority to CN2006800358867A priority patent/CN101273123B/zh
Priority to JP2008523415A priority patent/JP5755829B2/ja
Publication of FR2889200A1 publication Critical patent/FR2889200A1/fr
Application granted granted Critical
Publication of FR2889200B1 publication Critical patent/FR2889200B1/fr
Priority to IL188938A priority patent/IL188938A/en
Priority to JP2014255610A priority patent/JP5981525B2/ja
Priority to JP2016050940A priority patent/JP6235639B2/ja
Priority to JP2017121385A priority patent/JP2017169590A/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/069—Vascular Endothelial cells
    • C12N5/0692—Stem cells; Progenitor cells; Precursor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/28—Bone marrow; Haematopoietic stem cells; Mesenchymal stem cells of any origin, e.g. adipose-derived stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/44—Vessels; Vascular smooth muscle cells; Endothelial cells; Endothelial progenitor cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/48—Reproductive organs
    • A61K35/51—Umbilical cord; Umbilical cord blood; Umbilical stem cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Vascular Medicine (AREA)
  • Hematology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Genetics & Genomics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Wood Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
FR0508029A 2005-07-27 2005-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique Expired - Lifetime FR2889200B1 (fr)

Priority Applications (14)

Application Number Priority Date Filing Date Title
FR0508029A FR2889200B1 (fr) 2005-07-27 2005-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
JP2008523415A JP5755829B2 (ja) 2005-07-27 2006-07-27 Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途
EP06794234.2A EP1913130B1 (fr) 2005-07-27 2006-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
PCT/FR2006/001837 WO2007012764A2 (fr) 2005-07-27 2006-07-27 Système marqueur cellulaire/ligand, où le marqueur est du type eph, matériau cellulaire comprenant ce système, procédé de préparation et utilisation proangiogénique
CA2616712A CA2616712C (fr) 2005-07-27 2006-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
AU2006273928A AU2006273928B2 (en) 2005-07-27 2006-07-27 Cell/ligand marking system, wherein the marker is of Eph type, cell material comprising said system, method for preparing same and proangiogenetic use
US11/996,862 US8338169B2 (en) 2005-07-27 2006-07-27 Cell/ligand marking system, wherein the marker is of Eph type, cell material comprising said system, method for preparing same and proangiogenetic use
CN2006800358867A CN101273123B (zh) 2005-07-27 2006-07-27 标记物是Eph型标记物的细胞/配体标记系统，包含所述系统的细胞材料，其制备方法，和促血管生成的用途
ES06794234.2T ES2565675T3 (es) 2005-07-27 2006-07-27 Sistema marcador celular/ligando donde el marcador es de tipo Eph, material celular que comprende dicho sistema, proceso de preparación y utilización proangiogénica
DK06794234.2T DK1913130T3 (en) 2005-07-27 2006-07-27 Cellemarkør/ligand-system, hvor markøren er af eph-typen, cellemateriale, som omfatter systemet, fremgangsmåde til fremstilling deraf og proangiogen anvendelse
IL188938A IL188938A (en) 2005-07-27 2008-01-22 Cell / Ligand Marking System When the marker is an eph type, a cellular material containing this system, a method for its preparation and use to create blood vessels
JP2014255610A JP5981525B2 (ja) 2005-07-27 2014-12-17 Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途
JP2016050940A JP6235639B2 (ja) 2005-07-27 2016-03-15 Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途
JP2017121385A JP2017169590A (ja) 2005-07-27 2017-06-21 Ｅｐｈ型マ−カ−の細胞／リガンド標識システム、そのシステムからなる細胞物質ならびにその製造方法および前脈管形成としての用途

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
FR0508029A FR2889200B1 (fr) 2005-07-27 2005-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique

Publications (2)

Publication Number Publication Date
FR2889200A1 FR2889200A1 (fr) 2007-02-02
FR2889200B1 true FR2889200B1 (fr) 2008-01-04

Family

ID=36353668

Family Applications (1)

Application Number Title Priority Date Filing Date
FR0508029A Expired - Lifetime FR2889200B1 (fr) 2005-07-27 2005-07-27 Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique

Country Status (11)

Country Link
US (1) US8338169B2 (enExample)
EP (1) EP1913130B1 (enExample)
JP (4) JP5755829B2 (enExample)
CN (1) CN101273123B (enExample)
AU (1) AU2006273928B2 (enExample)
CA (1) CA2616712C (enExample)
DK (1) DK1913130T3 (enExample)
ES (1) ES2565675T3 (enExample)
FR (1) FR2889200B1 (enExample)
IL (1) IL188938A (enExample)
WO (1) WO2007012764A2 (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2909559B1 (fr) * 2006-12-06 2012-09-07 Inst Vaisseaux Et Du Sang Preparations cellulaires pour une utilisation comme agent stimulant la revascularisation
AU2008223817A1 (en) 2007-03-02 2008-09-12 National University Of Ireland, Galway Osteopontin for the prediction and treatment of cardiovascular diseases
FR2957799B1 (fr) * 2010-03-26 2012-08-17 Inst Des Vaisseaux Et Du Sang Compositions proangiogeniques, leur procede de preparation et leurs utilisations

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4240635C2 (de) * 1992-12-03 1997-07-10 Lothar Prof Dr Kanz Vermehrung hämatopoetischer Vorläuferzellen ex vivo sowieZusammensetzungen hämatopoetischer Wachstumsfaktoren
US5980887A (en) * 1996-11-08 1999-11-09 St. Elizabeth's Medical Center Of Boston Methods for enhancing angiogenesis with endothelial progenitor cells
US6864227B1 (en) 1998-04-13 2005-03-08 California Institute Of Technology Artery-and vein-specific proteins and uses therefor
WO2000031124A2 (en) 1998-11-20 2000-06-02 Mount Sinai Hospital Peptides that modulate the interaction of b class ephrins and pdz domains
US6610534B2 (en) 2000-10-05 2003-08-26 Novartis Ag Induction of blood vessel formation through administration of polynucleotides encoding sphingosine kinases
AU2002243623A1 (en) 2001-01-26 2002-08-06 Regeneron Pharmaceuticals, Inc. Methods of imaging and targeting vasculature
AU2002311792A1 (en) 2001-03-30 2002-10-15 President And Fellows Of Harvard College B-ephrin regulation of g-protein coupled chemoattraction; compositions and methods of use
US20050049194A1 (en) 2001-11-09 2005-03-03 Jonas Frisen Use of ephrins and related molecules to regulate cellular proliferation
AU2003232457A1 (en) 2002-05-29 2003-12-19 Curagen Corporation Compositions and methods of use for an ephrin rreceptor
US20040110150A1 (en) 2002-12-10 2004-06-10 Isis Pharmaceuticals Inc. Modulation of Ephrin-B2 expression
US7576074B2 (en) 2002-07-15 2009-08-18 Rice Kenneth D Receptor-type kinase modulators and methods of use
AU2003900541A0 (en) 2003-02-07 2003-02-20 Ludwig Institute For Cancer Research Modulation of cell adhesion and tumour cell metastasis
AU2004220459B2 (en) 2003-03-12 2010-08-05 Vasgene Therapeutics, Inc. Polypeptide compounds for inhibiting angiogenesis and tumor growth

Also Published As

Publication number Publication date
WO2007012764A2 (fr) 2007-02-01
JP6235639B2 (ja) 2017-11-22
ES2565675T3 (es) 2016-04-06
CN101273123B (zh) 2013-06-26
CN101273123A (zh) 2008-09-24
IL188938A0 (en) 2008-04-13
EP1913130B1 (fr) 2015-12-23
JP2017169590A (ja) 2017-09-28
JP5755829B2 (ja) 2015-07-29
AU2006273928B2 (en) 2012-02-16
IL188938A (en) 2014-09-30
AU2006273928A1 (en) 2007-02-01
JP2009505638A (ja) 2009-02-12
DK1913130T3 (en) 2016-03-29
US8338169B2 (en) 2012-12-25
JP5981525B2 (ja) 2016-08-31
FR2889200A1 (fr) 2007-02-02
EP1913130A2 (fr) 2008-04-23
CA2616712A1 (fr) 2007-02-01
JP2016127863A (ja) 2016-07-14
CA2616712C (fr) 2015-11-17
WO2007012764A3 (fr) 2007-05-31
US20090123431A1 (en) 2009-05-14
JP2015061536A (ja) 2015-04-02

Similar Documents

Publication Publication Date Title
FR2866330B1 (fr) Beton ultra haute performance et autoplacant, son procede de preparation et son utilisation.
FR2847166B1 (fr) Forme posologique comprenant des pastilles de tamsulosine enrobees, son procede de preparation et son utilisation
FR2910351B1 (fr) Catalyseur d'hydrotraitement, son procede de preparation et son utilisation.
FR2880823B1 (fr) Catalyseur d'hydrotraitement, son procede de preparation et et son utilisation
CY2200154T2 (el) Κινητες εργοστασιακες μοναδες και συστηματα, μεθοδοι για την παραγωγη αφαλατωμενου υδατος
PL1805913T3 (pl) System i sposób rozprowadzania sygnału bezprzewodowego
BRPI0411449A2 (pt) sistema de processamento de chamada
EP1800685A4 (en) PHARMACEUTICAL STEROID SAPONIN COMPOSITION, ITS PRODUCTION PROCESS AND ITS USE
FI20050357A0 (fi) Matkapäätelaitteen tarkan sijainnin määrittäminen, menetelmä ja laite
FR2910138B1 (fr) Materiau electrolyte de dispositif electrocommandable, son procede de fabrication, dispositif electrocommandable le comprenant et procede de fabrication dudit dispositif
ITMI20032168A1 (it) Sistema per movimentare salumi.
SG158133A1 (en) Method for reversing multiple resistance in animal cells
NL1029919A1 (nl) Therapeutische difenyletherliganden.
FR2889200B1 (fr) Systeme marqueur cellulaire/ligand, ou le marqueur est du type eph, materiau cellulaire comprenant ce systeme, procede de preparation et utilisation proangiogenique
FI20060029L (fi) Mittausjärjestelmä, mittausmenetelmä ja antennin uusi käyttö
FI20055175A0 (fi) Radioyhteysmenettely CDMA-pohjaisessa viestintäjärjestelmässä
FR2892646B1 (fr) Systeme catalytique heterogene et son utilisation.
FR2910137B1 (fr) Materiau electrolyte de dispositif electrocommandable, son procede de fabrication, dispositif electrocommandable le comprenant et procede de fabrication dudit dispositif
DE112008001256A5 (de) Mobilkommunikationsgeräte, geeignet zur Bestimmung von Entfernungen zu anderen Mobilkommunikationsgeräten, und das dazugehörige Verfahren
ES1058046Y (es) Vestidor para bebes con sistema de pesaje
FR2872705B1 (fr) Compositions contenant du nicorandil, procede de preparation et utilisation
FR2869713B1 (fr) Systeme de controle-commande par liaison sans fil d'un appareil d'automatisme.
ES1058793Y (es) Bloque macizo de pasta de yeso o escayola, machihembrado y biselado, para la construccion de tabiqueria interior y moldes para su fabricacion.
PT103140B (pt) Sistema de cobertura, em material cerâmico
Morotomi K. Goto, Public Policy for Culture and City: Making Space for Creativity and Creative Industries, Yuhikaku, 2005

Legal Events

Date Code Title Description
AU Other action affecting the ownership or exploitation of an industrial property right
CA Change of address
CD Change of name or company name
PLFP Fee payment

Year of fee payment: 12

PLFP Fee payment

Year of fee payment: 13